Page 5,193«..1020..5,1925,1935,1945,195..5,2005,210..»

Prime Therapeutics' specialty pharmacy receives URAC accreditation

Posted: Published on June 6th, 2013

ST. PAUL, Minn., June 5, 2013 /PRNewswire/ --Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that its specialty pharmacy, Prime Therapeutics Specialty Pharmacy, has received full accreditation from URAC. URAC is a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. "URAC accreditation recognizes Prime's unwavering commitment to the health and well being of its members," said Duane Barnes, senior vice president of consumer delivery, Prime Therapeutics. "From our state-of-the-art facility to extensive member education and support, Prime Therapeutics Specialty Pharmacy assures its members that their entire experience is of the utmost superior." URAC offers a wide range of quality benchmarking programs and services that keep pace with the rapid changes in the health care system, and provide a symbol of excellence for organizations to validate their commitment to quality and accountability. It made the decision to develop a Specialty Pharmacy accreditation program because it is one of the key distribution channels for pharmacy benefit management and extends URAC's consumer protection and empowerment efforts in managed care pharmacy. "By applying for and receiving URAC accreditation, Prime Therapeutics Specialty Pharmacy has demonstrated a commitment to quality health care," said William Vandervennet, URAC … Continue reading

Posted in Pharmacy | Comments Off on Prime Therapeutics' specialty pharmacy receives URAC accreditation

McKesson ideaShare 2013 to Focus on Helping Community Pharmacies Achieve Better Pharmacy Health

Posted: Published on June 6th, 2013

SAN FRANCISCO--(BUSINESS WIRE)-- McKesson Corporation will host thousands of community pharmacy owners and pharmacists at the McKesson ideaShare 2013 Conference, June 26-30, at the Venetian Resort Hotel in Las Vegas, NV. As McKessons annual community pharmacy trade show and conference, McKesson ideaShare is the premier education and networking event for independent retail pharmacies. This years event will provide a forum for attendees to share best practices and learn about solutions that address core aspects of running a better pharmacy business, achieving better results for patients and creating a better future for the pharmacy profession. For more than 30 years, weve seen tremendous energy and exchange of ideas at McKesson ideaShare, reinforcing the entrepreneurial and innovative spirit of community pharmacy, said Mark Walchirk, President, McKesson U.S. Pharmaceutical. McKesson ideaShare is truly an opportunity for community pharmacies to learn from - and inspire - one another to implement new ideas for long-term success. Attendees will benefit from a variety of educational and networking opportunities, including: Online registration is available at http://www.McKessonideaShare.com. About McKesson McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with … Continue reading

Posted in Pharmacy | Comments Off on McKesson ideaShare 2013 to Focus on Helping Community Pharmacies Achieve Better Pharmacy Health

New Gene Approach To Muscular Dystrophy – Neither Add Nor Delete, Just Edit

Posted: Published on June 6th, 2013

Duchenne Muscular Dystrophy, or DMD, the most common form of muscular dystrophy, is a genetic disorder caused by a mutation in a gene that can code for dystrophin, a protein in the muscles. This disorder is terminal, and death usually occurs before the age of 30 for the patients. DMD, which is characterized by muscle weakness and calf enlargement, affects mostly boys. It is estimated that there are roughly 30,000 DMD patients in the U.S., EU and Japan. Currently, there is no effective treatment for Duchenne Muscular Dystrophy. Stem cells, gene therapy or small-molecule drugs are some of the therapeutic strategies that are being tested as a treatment for DMD. The common gene therapy approach for DMD involves adding a healthy copy of the gene to make up for the faulty gene, and there may be some unforeseen issues associated with it. But guess what? Duke University biomedical engineers have found a new approach to gene therapy, which they believe could be safer and more stable than the current methods. In the new approach, the faulty gene is fixed by making use of genetic 'editing' technique, to help make it start producing a functional protein again. The novel method was … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on New Gene Approach To Muscular Dystrophy – Neither Add Nor Delete, Just Edit

The little girls who cannot play or go on holiday because rare form of epilepsy means that excitement could KILL them

Posted: Published on June 6th, 2013

Darcie and Evie Chapman, from Cheshire, both have Dravet Syndrome Their seizures can be triggered by excitement and extremes of temperature The syndrome also causes developmental delays and behavioural problems Their seizures are now successfully controlled using medication May be eligible for treatment with special high-fat diet when they are older By Emma Innes PUBLISHED: 05:37 EST, 5 June 2013 | UPDATED: 05:49 EST, 5 June 2013 415 shares 28 View comments Two-year-old twin sisters are not able to enjoy playing in the park or to go on holiday because the excitement could kill them. Darcie and Evie Chapman, from Warrington, Cheshire, are the only twins in the UK to have a severe form of epilepsy called Dravet Syndrome. Seizures can lead to SUDEP (sudden unexplained death in epilepsy patients) and the condition leads to delays in development, feeding problems, sleep problems and behavioural problems. Evie and Darcie Chapman have a severe form of epilepsy called Dravet Syndrome. It causes seizures, developmental delays, behavioural problems and feeding difficulties. They are pictured with parents, Mark and Natalie Here is the original post: The little girls who cannot play or go on holiday because rare form of epilepsy means that excitement could … Continue reading

Comments Off on The little girls who cannot play or go on holiday because rare form of epilepsy means that excitement could KILL them

Monmouth Medical Center epilepsy program receives national quality designation

Posted: Published on June 6th, 2013

The Epilepsy Monitoring Program at Monmouth Medical Center, Long Branch, recently received the distinction of a Level 3 designation from the National Association of Epilepsy Centers. The National Association of Epilepsy Centers has certified that Level 3 Centers have the professional expertise and facilities to provide the highest level evaluation and treatment for patients with complex epilepsy. The Monmouth Medical Center Epilepsy Monitoring Program offers state-of-the-art equipment that allows for continuous video-EEG monitoring the gold standard diagnostic investigation that can improve diagnostic accuracy when the diagnosis of epilepsy, particular seizure type, or location of onset is not clear by routine or prolonged EEG recordings.The accurate diagnosis of seizure type is essential to provide effective medical management and possible surgical treatment options to prospective patients, according to neurologist Joshua Mendelson, M.D., medical director of the Epilepsy Monitoring Program at Monmouth. Epilepsy is a common nervous system disorder in which clusters of nerve cells, or neurons, in the brain sometimes signal abnormally and can create nervous system disruption. Epilepsy can cause unusual sensations, as well as disturbances in emotions and behavior, along with seizures and loss of consciousness. The Epilepsy Foundation estimates that approximately one in 26 Americans will develop epilepsy at … Continue reading

Comments Off on Monmouth Medical Center epilepsy program receives national quality designation

A Third Of Autism Cases Also Have ADHD Symptoms

Posted: Published on June 6th, 2013

Editor's Choice Academic Journal Main Category: Autism Also Included In: ADHD Article Date: 05 Jun 2013 - 10:00 PDT Current ratings for: A Third Of Autism Cases Also Have ADHD Symptoms The study, which was published in Autism: The International Journal and Practice, identified a significant co-occurrence of ADHD and ASD. The researchers identified that children with ASD who showed signs of ADHD were much more likely to have impaired cognitive, social and adaptive functioning, compared to children with just an ASD. Social problems in children with autism and ADHD were had been analyzed in a previous study, which revealed that children with both autism and attention deficit or attention deficit hyperactivity disorders are four times more likely to bully than children in the general population. Most previous studies that have identified a link between ASD and ADHD have been based on patients seeking treatment from clinics (which makes them biased towards patients having more impairments). However, this current study provides a more accurate analysis (with reduced bias) of the link, as it only included infants or toddlers - before most cases of ADHD are diagnosed. Dr. Rebecca Landa, the senior author of the study and director of the Center … Continue reading

Comments Off on A Third Of Autism Cases Also Have ADHD Symptoms

Autism bill opponents make case against "mandate"

Posted: Published on June 6th, 2013

Georgia Commission on Mandates hears testimony on autism bill ATLANTA -- The opposition to the autism bill was finally out in the open during a meeting of the newly created state Commission on Mandates. "It's nice to see who they are and what you're up against," said Anna Bullard, the Toombs County mother who spent much of the winter lobbying on behalf of a bill that would require insurance coverage in Georgia for autism treatment. "Because the whole time we were at the capitol, we never saw anybody. Or heard anything. But we knew they were there." MORE | Continuing coverage of the Autism Gap The bill was named for Bullard's daughter Ava, an eight year old with autism. She has thrived under the type of treatment often denied to those lacking such insurance coverage. "And they all have compelling stories," said Kyle Jackson, lobbyist for the National Federation of Independent Businesses-- which opposes the bill. Like Bullard, Jackson spoke before the mandate commission Tuesday. "But at some point, we're going to make health insurance so expensive nobody's going to be able to afford it," Jackson told the commission. Lobbyists for the insurance industry also spoke against the bill, arguing … Continue reading

Comments Off on Autism bill opponents make case against "mandate"

Over-produced autism gene alters synapses, affects learning and behavior in mice

Posted: Published on June 6th, 2013

Public release date: 5-Jun-2013 [ | E-mail | Share ] Contact: Jim Barlow jebarlow@uoregon.edu 541-346-3481 University of Oregon EUGENE, Ore. -- (June 5, 2013) -- A gene linked to autism spectrum disorders that was manipulated in two lines of transgenic mice produced mature adults with irreversible deficits affecting either learning or social interaction. The findings, published in the May 29 issue of the Journal of Neuroscience, have implications for potential gene therapies but they also suggest that there may be narrow windows of opportunity to be effective, says principal investigator Philip Washbourne, a professor of biology and member of the University of Oregon's Institute of Neuroscience. The research, reported by an 11-member team from three universities, targeted the impacts of alterations in the gene neuroligin 1 -- one of many genes implicated in human autism spectrum disorders -- to neuronal synapses in the altered mice during postnatal development and as they entered adulthood. One group over-expressed the normal gene, the other a mutated version. Mice with higher-than-normal levels of the normal gene after a month had skewed synapses at maturity. Many were larger, appearing more mature, than normal. In these mice, Washbourne said, there were clear cognitive problems. "Behavior was … Continue reading

Comments Off on Over-produced autism gene alters synapses, affects learning and behavior in mice

Center for Autism and Related Disorders Opens New Treatment Center in Woburn, Massachusetts

Posted: Published on June 6th, 2013

Woburn, Massachusetts (PRWEB) June 05, 2013 Center for Autism and Related Disorders, Inc. (CARD), considered one of the worlds most effective treatment centers using evidence-based, state-of-the-art therapy, announces the opening of its CARD Boston treatment center, located at 331 Montvale Ave., 5th Floor, in Woburn. The grand opening will be held on Tuesday, June 25, 2013, from 5:00 p.m. to 7:30 p.m. The community is invited to meet the staff, tour the facility, and review the state-of-the-art CARD curriculum. Refreshments and childcare will be provided. CARD Boston provides a variety of services using the evidence-based principles of applied behavior analysis (ABA). Services include center-based treatment, home-based services and supervision, parent training, and school shadowing. We offer the community highly trained and experienced staff, a focus on evidence-based treatment, and the use of state-of-the-art technology, says clinical manager Ben Craighead, M.Ed, BCBA. CARD delivers cost-effective treatment that leads to measurable results for each client, including recovery with early, intensive ABA therapy. In August 2009, CARD researchers published "Retrospective Analysis of Clinical Records in 38 Cases of Recovery from Autism in the Annals of Clinical Psychiatry, showing that recovery from autism is possible. The comprehensive CARD model of treatment includes over 3,500 … Continue reading

Comments Off on Center for Autism and Related Disorders Opens New Treatment Center in Woburn, Massachusetts

InVivo Therapeutics’ Frank Reynolds Named a “CFO of the Year” Finalist by Boston Business Journal

Posted: Published on June 6th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that InVivos Chief Executive Officer and Chief Financial Officer Frank Reynolds has been named as a finalist in the fifth annual Boston Business Journals CFO of the Year Awards. Reynolds has been selected as a finalist in the Public Company category. The Boston Business Journals annual CFO of the Year Awards luncheon celebrates CFOs who have made a difference in their companies and organizations. At the luncheon, which is scheduled for July 31, 2013, finalists will be recognized and a winner for each of the five categories will be announced. In addition to Public Company, the categories include Small Private, Medium Private, Large Private and Non-Profit. The following CFOs are nominated for Public Company CFO of the Year: Donald W. Palette of Skyworks Solutions, Inc. (SWKS); Steven Lipiner of BNY Mellon Investment Management, BNY Mellon (BK); and Christopher Menard of Brightcove Inc. (BCOV). Said Reynolds, My thanks to our Director of Finance, Sean Moran, and his team, Albert Pasakarnis, Brian Luque, and Tatiana Monteiro, who are tasked with executing on plan and under … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics’ Frank Reynolds Named a “CFO of the Year” Finalist by Boston Business Journal

Page 5,193«..1020..5,1925,1935,1945,195..5,2005,210..»